Outcomes of Strabismus Surgery Following Teprotumumab Therapy

Authors

Grant Hilliard, Department of Ophthalmology, Hamilton Eye Institute, The University of Tennessee Health Science Center, Memphis, TN, USA.
Jaron Pruett, Department of Ophthalmology and Visual Sciences, Vanderbilt University Medical Center, Nashville, TN, USA.
Sean P. Donahue, Department of Ophthalmology and Visual Sciences, Vanderbilt University Medical Center, Nashville, TN, USA.
Federico G. Velez, Doheny Eye Institute, Department of Ophthalmology, University of California Los Angeles, Los Angeles, CA, USA; Stein Eye Institute, Department of Ophthalmology, University of California Los Angeles.
Jason H. Peragallo, Departments of Ophthalmology and Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.
Lauren Ditta, Department of Ophthalmology, Hamilton Eye Institute, The University of Tennessee Health Science Center, Memphis, TN, USA.
Mehdi Tavakoli, Department of Ophthalmology, George Washington University School of Medicine and Health Sciences, Washington, DC, USA.
Mary E. Hoehn, Department of Ophthalmology, Hamilton Eye Institute, The University of Tennessee Health Science Center, Memphis, TN, USA.
Annie F. Kuo, Department of Ophthalmology, Oregon Health & Science University, Portland, OR, USA.
Maanasa Indaram, Department of Ophthalmology, University of California San Francisco Health, San Francisco, CA, USA.
Natalie C. Kerr, Department of Ophthalmology, Hamilton Eye Institute, The University of Tennessee Health Science Center, Memphis, TN, USA. Electronic address: nkerr@uthsc.edu.

Document Type

Journal Article

Publication Date

1-6-2024

Journal

American journal of ophthalmology

DOI

10.1016/j.ajo.2024.01.005

Abstract

PURPOSE: To investigate the results of patients undergoing surgical treatment for strabismic diplopia in thyroid eye disease (TED) following teprotumumab. DESIGN: Multicenter, retrospective, case series. METHODS: We report 28 patients who underwent extraocular muscle surgery for strabismic diplopia after treatment with teprotumumab at 7 different academic centers. Elapsed time from last teprotumumab dose to the date of surgery, previous orbital decompression, primary preoperative horizontal and vertical deviation, surgical procedure, and 2-month postoperative results were collected from the patient records. RESULTS: Sixteen (57%) patients were diplopia-free after one surgery. Three (11%) chose prism spectacles to correct residual diplopia, 2 (7%) used compensatory head posture to resolve diplopia, and 1 (4%) had intermittent diplopia and was functionally improved (choosing no prisms or further surgery). These were considered treatment successes. Three (11%) patients required reoperation, and all were diplopia-free after their second procedure. CONCLUSIONS: Most patients requiring surgery for strabismic diplopia following teprotumumab achieve good outcomes with success rates comparable to series published before the availability of teprotumumab.

APA Citation

Hilliard, Grant; Pruett, Jaron; Donahue, Sean P.; Velez, Federico G.; Peragallo, Jason H.; Ditta, Lauren; Tavakoli, Mehdi; Hoehn, Mary E.; Kuo, Annie F.; Indaram, Maanasa; and Kerr, Natalie C., "Outcomes of Strabismus Surgery Following Teprotumumab Therapy" (2024). GW Authored Works. Paper 4203.
https://hsrc.himmelfarb.gwu.edu/gwhpubs/4203

Department

Ophthalmology